Drug intelligence / Profile preview

GLPG3221

Development stage: Unknown
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

GLPG3221 is a novel C2 corrector molecule being developed by Galapagos in collaboration with AbbVie for the treatment of cystic fibrosis (CF). It is designed to correct the function of the faulty cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting class 2 mutations, and is intended to be part of a triple combination therapy alongside a C1 corrector and a potentiator. This investigational therapy aims to restore healthy chloride transport in patients with CF, particularly those with the F508del mutation.

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on GLPG3221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG3221.

Explore the full profile